Therapeutic Effect of Liposomal Prostaglandin E in Acute Lower Limb Ischemia As an Adjuvant to Hybrid Procedures

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2013 Jul 10

PMID 23837069

Citations 3

Authors

Jianlin Li

Bing Wang

Yue Wang

Fei Wu

Panfeng Li

Yang Li

Lei Zhao

Wenjun Cui

Yu Ding

Qian An

Jiangtao Si

Affiliations

Soon will be listed here.

Abstract

Prostaglandin E (PGE) is widely used in the treatment of limb ischemia for its potent vasodilatory and antiplatelet effects. In order to assess the curative effect of liposomal PGE (lipo-PGE) as an adjuvant to surgery in patients with acute lower limb ischemia (ALLI), 204 patients who underwent hybrid procedures (operative thromboembolectomy or bypass and necessary endovascular interventions) for ALLI were randomly divided into a blank control group and a lipo-PGE group (intravenous infusion of 20 g/day for 12-14 consecutive days following surgery). Patients were followed-up for 6 months after surgical revascularization for clinical events. The primary study endpoint, which was the combined incidence of perioperative (30 days) mortality (POM) and major adverse limb events (MALE; amputation or major intervention), was significantly reduced in patients treated with lipo-PGE (5.1% compared with 13.2% in the control group). The overall incidence of clinical events, including POM, MALE and major adverse cardiovascular events, was significantly reduced in patients receiving lipo-PGE (8.2%) compared with the controls (20.8%). Hybrid procedures are an improved method for treating ALLI and may remedy underlying lesions of vessels following thromboembolectomy.

Citing Articles

Acute lower extremity arterial thrombosis after intraocular foreign body removal under general anesthesia: A case report and review of literature.

Jeon S, Hong J, Lee H, Kim E, Lee H, Kim Y World J Clin Cases. 2021; 9(27):8232-8241.

PMID: 34621886 PMC: 8462198. DOI: 10.12998/wjcc.v9.i27.8232.

Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis.

Peters L, Jans A, Bartneck M, van der Vorst E J Clin Med. 2021; 10(14).

PMID: 34300351 PMC: 8306310. DOI: 10.3390/jcm10143185.

Liposomal Formulations in Clinical Use: An Updated Review.

Bulbake U, Doppalapudi S, Kommineni N, Khan W Pharmaceutics. 2017; 9(2).

PMID: 28346375 PMC: 5489929. DOI: 10.3390/pharmaceutics9020012.

References

Willerson J, Yao S, MCNATT J, Cui K, Anderson H, SWENSEN C . Liposome-bound prostaglandin E1 often prevents cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation. 1994; 89(4):1786-91. DOI: 10.1161/01.cir.89.4.1786. View

Bosma H, Jorning P . Intra-operative arteriography in arterial embolectomy. Eur J Vasc Surg. 1990; 4(5):469-72. DOI: 10.1016/s0950-821x(05)80785-6. View

Brass E, Anthony R, Dormandy J, Hiatt W, Jiao J, Nakanishi A . Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 2006; 43(4):752-9. DOI: 10.1016/j.jvs.2005.11.041. View

Dormandy J, Rutherford R . Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000; 31(1 Pt 2):S1-S296. View

Zaraca F, Stringari C, Ebner J, Ebner H . Routine versus selective use of intraoperative angiography during thromboembolectomy for acute lower limb ischemia: analysis of outcomes. Ann Vasc Surg. 2010; 24(5):621-7. DOI: 10.1016/j.avsg.2009.12.006. View

Chu-fan L, Xing W, Xun H, Gui-Fu W, Cheng-heng H, Zhi-Min D . Protective effect of lipid microspheres 1 on myocardial injury following elective percutaneous coronary intervention in patients with angina pectoris: a pilot study. J Cardiovasc Med (Hagerstown). 2011; 12(11):790-4. DOI: 10.2459/JCM.0b013e32834bb47c. View

Schrijver A, Moll F, De Vries J . Hybrid procedures for peripheral obstructive disease. J Cardiovasc Surg (Torino). 2010; 51(6):833-43. View

Gianetti J, De Caterina M, De Cristofaro T, Ungaro B, Guercio R, De Caterina R . Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease. Am Heart J. 2001; 142(4):733-9. DOI: 10.1067/mhj.2001.118109. View

Gao Y, Xu P, Chen L, Li Y . Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect. Int J Pharm. 2009; 387(1-2):263-71. DOI: 10.1016/j.ijpharm.2009.12.019. View

10.

Taylor C, McGaw J, Rigby A, Threlfall D, Karmel J . Pilot safety study of liposomal prostaglandin (PGE1) in respiratory exacerbations in cystic fibrosis. J Cyst Fibros. 2004; 1(2):90-3. DOI: 10.1016/s1569-1993(02)00034-6. View

11.

Nypaver T, Whyte B, Endean E, Schwarcz T, HYDE G . Nontraumatic lower-extremity acute arterial ischemia. Am J Surg. 1998; 176(2):147-52. DOI: 10.1016/s0002-9610(98)00163-9. View

12.

Conte M, Geraghty P, Bradbury A, Hevelone N, Lipsitz S, Moneta G . Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009; 50(6):1462-73.e1-3. DOI: 10.1016/j.jvs.2009.09.044. View

13.

Matsagkas M, Kouvelos G, Arnaoutoglou E, Papa N, Labropoulos N, Tassiopoulos A . Hybrid procedures for patients with critical limb ischemia and severe common femoral artery atherosclerosis. Ann Vasc Surg. 2011; 25(8):1063-9. DOI: 10.1016/j.avsg.2011.07.010. View

14.

Lipsitz E, Veith F, Wain R . Digital fluoroscopy as a valuable adjunct to open vascular operations. Semin Vasc Surg. 2003; 16(4):280-90. DOI: 10.1053/j.semvascsurg.2003.08.006. View

15.

Shin M, Song S, Kim J, Kim S, Joh J, Lee S . Effectiveness of intraportal prostaglandin E1 administration after liver transplantation. Transplant Proc. 2012; 44(2):500-4. DOI: 10.1016/j.transproceed.2012.01.070. View

16.

Murota H, Kotobuki Y, Umegaki N, Tani M, Katayama I . New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer. Rheumatol Int. 2008; 28(11):1127-35. DOI: 10.1007/s00296-008-0589-5. View

17.

Mohler 3rd E, Giri J . Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Curr Med Res Opin. 2008; 24(9):2509-22. DOI: 10.1185/03007990802274379. View

18.

Aune S, Trippestad A . Operative mortality and long-term survival of patients operated on for acute lower limb ischaemia. Eur J Vasc Endovasc Surg. 1998; 15(2):143-6. DOI: 10.1016/s1078-5884(98)80135-4. View

19.

Pemberton M, Varty K, Nydahl S, Bell P . The surgical management of acute limb ischaemia due to native vessel occlusion. Eur J Vasc Endovasc Surg. 1999; 17(1):72-6. DOI: 10.1053/ejvs.1998.0709. View

20.

Braithwaite B, Davies B, Birch P, Heather B, Earnshaw J . Management of acute leg ischaemia in the elderly. Br J Surg. 1998; 85(2):217-20. DOI: 10.1046/j.1365-2168.1998.00577.x. View